Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px

Person › Details

Ugur Sahin (BioNTech AG)

Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)

	Organisation	BioNTech AG
	Today	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Former/major organisation	Ribological GmbH
	Today	BioNTech RNA Pharmaceuticals GmbH
	Group	BioNTech (Group)
	Product	drug discovery
	Product 2	cancer drug

Record changed: 2024-11-13

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Ugur Sahin

[1] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
[2] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
[3] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
[4] BioNTech SE. (5/29/24). "Press Release: BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem". Mainz & Oslo....
[5] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
[6] BioNTech SE. (1/9/24). "Press Release: BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference". Mainz....
[7] BioNTech SE. (12/18/23). "Press Release: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda". Kigali....
[8] BioNTech SE. (8/7/23). "Press Release: BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update". Mainz....
[9] BioNTech SE. (4/3/23). "Press Release: BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors". Mainz & Shanghai....
[10] BioNTech AG. (3/20/23). "Press Release: BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications". Mainz & Rockville, MD....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]